For more than two decades, every medication available for narcolepsy type 1 has done the same thing: managed symptoms without addressing why they exist. Stimulants prop open heavy eyelids. Sodium oxybate consolidates fractured nighttime sleep. Antidepressants suppress cataplexy. None of them touch the underlying problem — the destruction of the roughly 70,000 hypothalamic neurons that produce orexin, the neuropeptide that stabilizes wakefulness.
That may change within months. The FDA has accepted Takeda's new drug application for oveporexton (TAK-861) and granted it priority review, with a target action date in the third quarter of 2026. If approved, it would be the first orexin receptor agonist — and the first treatment of any kind designed to restore the missing signal at the heart of the disease.
What the Phase 3 Trials Showed
The application rests on two pivotal trials: FirstLight, which randomized 168 patients across three arms (twice-daily 2 mg, 1 mg, and placebo), and RadiantLight, which enrolled 105 patients in two arms (2 mg and placebo). Both met all primary and secondary endpoints at 12 weeks.
The results were striking across every major measure of the disease:
- Wakefulness: Patients on the 2 mg dose gained an average of 17.2 minutes on the Maintenance of Wakefulness Test (MWT), a standardized measure of the ability to stay awake. At baseline, participants averaged just 5 minutes — barely able to resist sleep in a quiet room. By week 12, most had crossed the 20-minute threshold considered normal.
- Daytime sleepiness: Roughly 85% of participants achieved Epworth Sleepiness Scale scores of 10 or below, the range typical of healthy adults. The mean ESS drop was 9.75 points on the 2 mg dose, compared to 6.13 for placebo.
- Cataplexy: Participants entered the trials experiencing a median of 26 cataplexy episodes per week — sudden, emotionally triggered episodes of muscle weakness that can cause falls, slurred speech, or total collapse. The drug reduced attack frequency by more than 80% from baseline, and median cataplexy-free days rose from zero at baseline to four or five per week.
No serious treatment-related adverse events were reported. The most common side effects were insomnia and urinary urgency, both consistent with the drug's pharmacological profile.
How It Works
Oveporexton is an oral orexin receptor 2 (OX2R)-selective agonist. Rather than compensating for orexin's absence by boosting downstream neurotransmitters — the strategy behind stimulants and wake-promoting agents like modafinil — it binds directly to the same receptor that orexin itself activates.
In narcolepsy type 1, autoimmune destruction of orexin-producing neurons leaves the brain without the stabilizing signal that keeps wakefulness consolidated and prevents inappropriate intrusions of REM sleep features (including cataplexy, sleep paralysis, and hypnagogic hallucinations). By mimicking orexin's action at the receptor level, oveporexton aims to restore the function the missing neurons once provided.
The drug is taken twice daily in tablet form, a logistical improvement over sodium oxybate, which requires two doses separated by several hours during the night and carries restrictions around food timing and alcohol use.
A Condition Often Misunderstood
Narcolepsy type 1 affects approximately 1 in 2,000 people, translating to roughly 140,000 to 175,000 patients in the United States alone. Despite its severity — cataplexy attacks can be triggered by laughter, surprise, or anger, making everyday social interactions unpredictable — the condition takes an average of 8 to 15 years to diagnose from symptom onset.
Much of that delay stems from the subtlety of early symptoms. Excessive daytime sleepiness is often attributed to poor sleep habits, depression, or laziness before the underlying orexin deficiency is identified. Meanwhile, the neurodegenerative process that destroys orexin neurons — believed to be autoimmune in most cases — has already run its course by the time most patients receive a diagnosis.
The Orexin Agonist Race
Takeda is not alone in pursuing this mechanism. Alkermes received FDA Breakthrough Therapy designation for alixorexton, its own orexin 2 receptor agonist, in January 2026 and initiated a global Phase 3 program in the first quarter of 2026. The competition signals broad pharmaceutical confidence that orexin restoration, rather than symptom suppression, represents the future of narcolepsy treatment.
The investment trend extends beyond narcolepsy. In March 2026, Eli Lilly completed a $7.8 billion acquisition of Centessa Pharmaceuticals, driven largely by Centessa's orexin-based pipeline — a deal that industry analysts described as an "orexin gold rush." While Lilly's initial focus is on insomnia (using orexin antagonists, which block the receptor rather than activate it), the acquisition reflects growing recognition that the orexin system is a central lever in sleep-wake regulation with therapeutic applications across multiple disorders.
What This Means for Patients
Patients currently managing narcolepsy type 1 should continue their existing treatment regimens. Oveporexton has not yet been approved, and even with priority review, the FDA decision is not expected until the third quarter of 2026, with commercial availability to follow.
However, the clinical data represent a meaningful shift. For the first time, a drug has demonstrated the ability to restore near-normal wakefulness and dramatically reduce cataplexy by targeting the biological root of the disease rather than masking its downstream effects. If the FDA concurs, patients who have spent years cycling through stimulants, sodium oxybate, and antidepressants may gain access to a treatment that addresses what went wrong in the first place.
Patients interested in learning more can speak with their sleep specialist or neurologist about upcoming treatment options and monitor updates from Takeda's clinical pipeline.
